CRD-4730

Cardurion Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	CRD-4730
Sponsor	Cardurion Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2 Study of CRD-4730 in CPVT (PHASE2)
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CRD-4730 CI brief — competitive landscape report
CRD-4730 updates RSS · CI watch RSS
Cardurion Pharmaceuticals, Inc. portfolio CI